Minocycline
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Minocycline: From Bacterial Infections to Punctate Epithelial Keratoconjunctivitis
One-Sentence Summary
Minocycline is a tetracycline antibiotic, used to treat a range of bacterial infections. The TxGNN model predicts it may be effective for punctate epithelial keratoconjunctivitis. This is a model prediction only: 0 clinical trials and 0 publications were retrieved for this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Bacterial infections (tetracycline antibiotic; the SAHPRA-approved indication text is not available in this record) |
| Predicted New Indication | Punctate epithelial keratoconjunctivitis |
| TxGNN Prediction Score | 99.63% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Marketed |
| Number of SAHPRA Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in this record. Minocycline is a tetracycline antibiotic. Its efficacy in bacterial infections is established, and mechanistically it may be applicable to inflammatory eye-surface disease.
A plausible link is the anti-inflammatory and matrix metalloproteinase (MMP)-inhibiting activity reported for tetracyclines on the ocular surface. Punctate epithelial keratoconjunctivitis involves inflammation and damage to the surface of the cornea and conjunctiva.
This is a hypothesis, not evidence. The high score reflects a pattern in the knowledge graph and is not clinical proof. Route compatibility has not been assessed. The only registered South African product is an oral tablet, and ocular use may require a different route or formulation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
South Africa Market Information
| Registration Number | Product Name | Dosage Form |
|---|---|---|
| Reg. No. 28/20.1.1/0574 | Sandoz Minocycline | Tablet (oral) |
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or publications (evidence level L5), and the mechanism data and SAHPRA safety information are missing. The only local product is an oral tablet, whose fit for an ocular indication is unassessed. The prediction is a hypothesis for further research and should not be used for clinical decisions.
To proceed, the following is needed:
- The SAHPRA package insert (warnings and contraindications), which blocks any safety screening
- Mechanism of action data, for example from DrugBank
- A literature and trial search specific to minocycline in punctate epithelial keratoconjunctivitis
- A route-of-administration assessment (oral tablet versus ocular use)
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.